How has the understanding and prevalence of liver disease changed over time?

Historically, infectious agents and toxins like alcohol were primary causes. While these remain relevant, metabolic dysfunction associated with modern lifestyles is now the most prevalent cause globally, often overshadowing other factors.

Why is Hepatitis B considered an outlier in terms of cancer risk compared to Hepatitis C?

Hepatitis C cancer risk increases with fibrosis progression to cirrhosis. However, Hepatitis B can lead to liver cancer (hepatocellular carcinoma) even in the absence of advanced fibrosis or cirrhosis, making early screening critical regardless of scar tissue.

What is hepatic steatosis and how is it accurately diagnosed?

Hepatic steatosis is the accumulation of greater than 5% fat in liver cells. While basic ultrasounds require over 30% fat for detection, more sensitive methods like vibration-controlled transient elastography (FibroScan) and MRI Proton Density Fat Fraction (MRI-PDFF) can detect it at lower thresholds.

How does alcohol metabolism contribute to liver injury, and why is acetylaldehyde problematic?

When alcohol is metabolized, it produces acetylaldehyde as an intermediary. When the liver's capacity is overwhelmed, acetylaldehyde accumulates, attracting inflammatory cells and causing peroxidation, leading to liver cell damage and fat deposition.

What is the new terminology for fatty liver disease, replacing NAFLD and NASH?

NAFLD (non-alcoholic fatty liver disease) has been renamed MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). NASH (non-alcoholic steatohepatitis) is now MASH (Metabolic Dysfunction Associated Steatohepatitis). This change emphasizes the metabolic root cause and reduces stigma.

What is the prevalence of MASLD, and should people be screened for it?

MASLD affects an estimated 25-35% of the US population, making it highly prevalent. While population-wide screening is not currently recommended, individuals with metabolic risk factors, obesity, or diabetes should be assessed for early detection and intervention.

Beyond weight loss, what lifestyle interventions are crucial for improving MASLD?

In addition to a balanced diet focused on lowering glycemic load and avoiding processed foods, regular physical activity combining aerobic and resistance training is vital. Sleep quality also plays a role. Coffee consumption (up to three cups daily) has shown benefits for liver health and fibrosis.

Are GLP-1 agonists effective in treating MASLD, and what are the considerations for their use?

GLP-1 agonists like semaglutide and tirzepatide have a profound impact on weight loss and insulin sensitivity, making them effective for MASLD, especially in diabetic or obese patients. However, discussions should include potential muscle loss and the challenge of sustaining weight loss after discontinuation.

Can liver fibrosis and cirrhosis be reversed, and what are the stages of liver damage?

Traditional teaching suggested cirrhosis was irreversible, but evidence indicates early cirrhosis (stage 4 fibrosis) can be reversible. Liver damage progresses through stages: steatosis (fat accumulation), steatohepatitis (fat plus inflammation), and then fibrosis stages (1-4), with stage 4 being cirrhosis.

What is the cancer risk associated with MASLD, and at what stage does screening become vital?

People with MASLD face an increased risk of hepatocellular carcinoma (HCC). This risk significantly increases once cirrhosis (stage 4 fibrosis) is reached, at an estimated 3-5% per year, warranting regular screening every six months. Earlier screening for those with less advanced disease is an active area of research.

What new medications are on the horizon for treating MASLD?

Resmetirom, a thyroid hormone receptor agonist, has shown promising late-stage efficacy. Other agents like FGFs and FXR agonists are also being investigated. These therapies aim to target fibrosis and steatosis, potentially alongside weight loss strategies.

302 - Confronting a metabolic epidemic: how to prevent, diagnose, & manage liver disease

Peter Attia MD

Science & Technology4 min read158 min video

May 20, 2024|79,669 views|1,188|125

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

On this page

TL;DR

Liver disease is a metabolic epidemic; focus on lifestyle, new treatments, and early detection.

Key Insights

The liver has over 300 functions, is vital, and lacks external support systems like dialysis for kidneys.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing epidemic, often underdiagnosed and linked to broader metabolic and cardiovascular risks.

Transaminases (ALT/AST) are markers of liver cell injury, not direct function, and 'normal' ranges have shifted due to population health decline.

Early-stage liver disease, while potentially reversible, carries significant long-term risks for cardiovascular disease and cancer.

Lifestyle interventions (exercise, diet, sleep) are crucial, and emerging treatments target specific pathways of liver fat accumulation and inflammation.

New nomenclature like MASLD aims to destigmatize liver disease and better reflect underlying pathophysiology.

THE CRITICAL ROLE AND VULNERABILITY OF THE LIVER

The liver, a vital organ weighing about 3.5 pounds, performs over 300 essential functions, including metabolism, immune support, detoxification, and synthesizing proteins crucial for blood clotting. Unlike other vital organs, the liver lacks external support systems, making its health paramount. Historically, liver injury was primarily attributed to infectious agents like hepatitis or toxins like alcohol. However, the modern environment has shifted the landscape, making metabolic dysfunction a leading cause of liver disease.

THE RISE OF METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

MASLD, formerly known as NAFLD, is now a predominant cause of liver disease globally, affecting an estimated 25-35% of the population. This condition involves fat accumulation in the liver, often stemming from excess caloric intake and metabolic dysfunction, particularly concerning glucose and lipid metabolism. It's critical to distinguish MASLD from alcohol-related liver disease, as the underlying mechanisms and potential treatments differ.

DIAGNOSTIC CHALLENGES AND THE UNSUNG ROLE OF IMAGING

Diagnosing MASLD early can be challenging. Standard ultrasounds may miss early fat accumulation, requiring more sensitive imaging techniques like vibration-controlled transient elastography (VCTE) or MRI-based proton density fat fraction (PDFF). Liver stiffness measurements, often obtained via elastography, provide crucial information about fibrosis, or scarring, within the liver. Relying solely on aminotransferases (ALT/AST), which are markers of cell injury rather than liver function, can be misleading, as 'normal' lab values have become less indicative of optimal health due to population-wide declines in metabolic health.

PROGRESSION AND THE MULTIFACETED RISKS OF LIVER DISEASE

MASLD progresses through stages: steatosis (fat accumulation), steatohepatitis (fat with inflammation), fibrosis (scarring), and cirrhosis (advanced scarring). The progression is often slow, with 5-7 years between stages, offering a window for intervention. Crucially, even early-stage MASLD significantly increases the risk of cardiovascular events and certain cancers, often outweighing the immediate risk to the liver itself. This underscores the importance of a holistic health approach.

THERAPEUTIC STRATEGIES: LIFESTYLE, MEDICATIONS, AND FUTURE DIRECTIONS

The cornerstone of managing MASLD remains lifestyle modification, including weight loss, regular exercise, and a balanced diet emphasizing complex carbohydrates over refined sugars and processed foods. Emerging treatments, such as GLP-1 receptor agonists, show promise by addressing weight, insulin sensitivity, and potentially direct liver effects. New drug classes targeting thyroid hormone receptors and other pathways are in late-stage development, aiming to reduce fat accumulation and fibrosis, though many require combination therapy and further research for diverse populations.

THE NUANCES OF ALCOHOL'S IMPACT AND INDIVIDUAL VARIABILITY

Alcohol's metabolism in the liver generates acetaldehyde, a toxic intermediate that can lead to inflammation, fat deposition, and cell damage. Individual responses to alcohol vary significantly due to genetic factors, sex, and hormonal differences. While moderate alcohol consumption's effects are debated, even low levels can pose risks, particularly concerning cancer and other organ damage. Quantifying alcohol intake accurately and understanding personal risk factors are key steps in counseling and intervention.

ADDRESSING RARE CAUSES AND THE IMPORTANCE OF SPECIALIZED CONSULTATION

While MASLD is common, it's essential to consider rarer causes of liver disease, especially in outlier cases (e.g., lean individuals with advanced liver damage). Conditions like hereditary hemochromatosis or rare genetic lipid disorders can mimic MASLD but require distinct diagnostic and treatment approaches. When standard tests are discordant or a patient presents with unusual characteristics, involving specialists is crucial for accurate diagnosis and appropriate family screening.

THE EVOLVING UNDERSTANDING OF LIVER DISEASE NOMENCLATURE AND SCREENING

The shift from terms like NAFLD/NASH to MASLD and the recognition of overlapping conditions like 'metabolic-alcohol-related liver disease' (MetALD) reflects a more nuanced understanding of liver disease etiology. This includes acknowledging that metabolic dysfunction and alcohol consumption can co-exist and independently contribute to liver damage. While formal screening recommendations for MASLD are still evolving, proactive assessment of metabolic health and risk factors is encouraged for early detection and intervention.

Mentioned in This Episode

●Supplements

●Products

●Tools

●Organizations

●Concepts

●People Referenced

Common Questions

The liver performs over 300 functions, including regulating blood glucose, synthesizing proteins for blood clotting, and detoxifying various substances. It's often underappreciated and lacks extracorporeal support, highlighting its irreplaceable role in the body.

Topics

Metabolic Dysfunction Associated Steatotic Liver Disease NASH MASH Liver Transplant Hepatitis Cirrhosis Fibrosis Aminotransferases Test Liver Function Tests Liver Cancer

Mentioned in this video

organizationBaylor College of Medicine

Where Dr. Julia Wattacheril attended medical school and residency.

productMars machine

A type of device developed for extracorporeal liver support.

conceptKing's College Criteria

Diagnostic criteria used in acute liver failure, particularly for acetaminophen overdose.

toolVibration Controlled Transient Elastography (FibroScan)

A point-of-care technique using ultrasound and vibrations to measure liver fat and stiffness (CAP score and scar score).

drugOcaliva (Obeticholic Acid)

An FXR Agonist that was the first approved treatment for primary biliary cholangitis, now also explored for MASLD.

personWill Lee

Researcher at UT Southwestern whose work encapsulated variables in liver transplantation for acute liver failure.

conceptAlanine Aminotransferase (ALT)

An enzyme primarily found in liver cells; elevated levels indicate liver cell stress or damage.

conceptHOMO-IR (Homeostatic Model Assessment for Insulin Resistance)

A method to assess insulin resistance based on fasting glucose and insulin levels, favored by Dr. Wattacheril.

conceptPhosphatidylethanol (Peth)

A longer-range metabolite that can be measured to assess alcohol intake over weeks, similar to A1C for glucose.

personThomas Starzl

Pioneering surgeon who led the first successful liver transplantations in the 1960s.

toolMRI pdff (Proton Density Fat Fraction)

A dedicated MRI technique used to accurately quantify liver fat, often used in research but becoming more clinically available.

drugAzetam (ezetimibe)

A medication that can cause elevated transaminases in some patients, potentially contributing to Peter Attia's slightly higher AST/ALT.

conceptNASH score

Proprietary serum-based tests that provide scores for steatosis and fibrosis, though may leave intermediate risk assessment uncertain.

conceptMASLD (Metabolic Dysfunction Associated Steatotic Liver Disease)

The new umbrella term for fatty liver disease associated with metabolic dysfunction, replacing NAFLD.

conceptFibrosis-4 (Fib-4)

A simple calculator using routine lab values to estimate liver fibrosis, useful for initial assessment.

conceptHereditary Hemochromatosis

A relatively rare disease with high oncologic potential, causing iron accumulation in the liver.

conceptAspartate Aminotransferase (AST)

An enzyme found in liver, muscle, and other tissues; elevated levels indicate cell damage, often liver-related.

conceptGamma-glutamyl transferase (GGT)

An enzyme that can be elevated in liver injury, particularly in cholestatic liver diseases or those affecting bile ducts, more common in pediatric fatty liver disease.

conceptMASH (Metabolic Dysfunction Associated Steatohepatitis)

The new term for the inflammatory form of MASLD, replacing NASH.

drugResmetirom

A thyroid hormone receptor agonist showing promise in phase three clinical trials for MASLD, targeting fibrosis and steatosis.

supplementMethotrexate